INT204122

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.47
First Reported 2007
Last Reported 2007
Negated 0
Speculated 0
Reported most in Body
Documents 13
Total Number 19
Disease Relevance 22.98
Pain Relevance 3.04

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

transport (GJA8) plasma membrane (GJA8)
GJA8 (Homo sapiens)
Pain Link Frequency Relevance Heat
headache 28 99.76 Very High Very High Very High
ischemia 24 99.16 Very High Very High Very High
corticosteroid 112 98.68 Very High Very High Very High
Inflammation 283 98.64 Very High Very High Very High
Infliximab 455 98.20 Very High Very High Very High
abdominal pain 28 97.96 Very High Very High Very High
Angina 43 96.28 Very High Very High Very High
Adalimumab 231 91.20 High High
Etanercept 42 89.20 High High
Pain 14 74.52 Quite High
Disease Link Frequency Relevance Heat
Pathologic Dilatation 600 100.00 Very High Very High Very High
Diabetes Mellitus 91 99.92 Very High Very High Very High
Hypertension 74 99.92 Very High Very High Very High
Headache 28 99.76 Very High Very High Very High
Congenital Anomalies 12 99.76 Very High Very High Very High
Coronary Artery Disease 300 99.72 Very High Very High Very High
Nasopharyngitis 21 99.36 Very High Very High Very High
Disease 722 99.24 Very High Very High Very High
INFLAMMATION 293 98.64 Very High Very High Very High
Abdominal Pain 28 97.96 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
CAE were presented in Table 2.
Gene_expression (presented) of CAE associated with pathologic dilatation
1) Confidence 0.47 Published 2007 Journal Mediators of Inflammation Section Body Doc Link PMC1804298 Disease Relevance 0.75 Pain Relevance 0
CAE patients were found and 13 of them were excluded
Gene_expression (found) of CAE associated with pathologic dilatation
2) Confidence 0.41 Published 2007 Journal Mediators of Inflammation Section Body Doc Link PMC1804298 Disease Relevance 1.49 Pain Relevance 0.32
significantly higher in the CAE group than the O-CAD
Gene_expression (group) of CAE associated with coronary artery disease and pathologic dilatation
3) Confidence 0.41 Published 2007 Journal Mediators of Inflammation Section Body Doc Link PMC1804298 Disease Relevance 2.10 Pain Relevance 0
hs-CRP and age and DM in CAE group, whereas a
Gene_expression (group) of CAE associated with diabetes mellitus and pathologic dilatation
4) Confidence 0.41 Published 2007 Journal Mediators of Inflammation Section Body Doc Link PMC1804298 Disease Relevance 2.25 Pain Relevance 0.15
levels were similar in both CAE and O-CAD [9, 10].
Gene_expression (similar) of CAE associated with coronary artery disease and pathologic dilatation
5) Confidence 0.41 Published 2007 Journal Mediators of Inflammation Section Body Doc Link PMC1804298 Disease Relevance 1.73 Pain Relevance 0.37
levels were significantly higher in CAE group than O-CAD
Gene_expression (group) of CAE associated with coronary artery disease and pathologic dilatation
6) Confidence 0.41 Published 2007 Journal Mediators of Inflammation Section Body Doc Link PMC1804298 Disease Relevance 0.85 Pain Relevance 0
However, there was no correlation between hs-CRP and DM and HT in CAE group (r = 0.681, P = .067; r = 0.673, P = .069).
Gene_expression (group) of CAE associated with diabetes mellitus, hypertension and pathologic dilatation
7) Confidence 0.41 Published 2007 Journal Mediators of Inflammation Section Body Doc Link PMC1804298 Disease Relevance 2.11 Pain Relevance 0
any correlation between hs-CRP and age in CAE group is
Gene_expression (group) of CAE associated with pathologic dilatation
8) Confidence 0.41 Published 2007 Journal Mediators of Inflammation Section Body Doc Link PMC1804298 Disease Relevance 2.42 Pain Relevance 0.15
was found in CAE group (r = 0.401, P = .09; r = 0.173,
Gene_expression (group) of CAE associated with pathologic dilatation
9) Confidence 0.41 Published 2007 Journal Mediators of Inflammation Section Body Doc Link PMC1804298 Disease Relevance 2.04 Pain Relevance 0
levels in CAE.
Gene_expression (levels) of CAE associated with pathologic dilatation
10) Confidence 0.41 Published 2007 Journal Mediators of Inflammation Section Body Doc Link PMC1804298 Disease Relevance 1.82 Pain Relevance 0.30
significant correlation between average diameter of CAE and hs-CRP

(r = 0.244, P = .129), and a weak correlation was

Gene_expression (diameter) of CAE associated with pathologic dilatation
11) Confidence 0.41 Published 2007 Journal Mediators of Inflammation Section Body Doc Link PMC1804298 Disease Relevance 1.25 Pain Relevance 0
whereas 20%–30% of cases may be due to congenital anomalies

[2–4], and CAE was found in the range of

Gene_expression (found) of CAE associated with congenital anomalies and pathologic dilatation
12) Confidence 0.36 Published 2007 Journal Mediators of Inflammation Section Body Doc Link PMC1804298 Disease Relevance 1.18 Pain Relevance 0.07
Moreover, CZP is synthesized by fed-batch fermentation in Escherichia coli.
Gene_expression (synthesized) of CZP
13) Confidence 0.09 Published 2007 Journal Core Evidence Section Body Doc Link PMC3012434 Disease Relevance 0 Pain Relevance 0.22
Regarding some of these aspects, subanalyses from PRECiSE 2 have shown that CZP was effective in most patients regardless of prior use of infliximab or concomitant immunosuppressant or glucocorticoid treatment (Colombel et al. 2007c).
Gene_expression (effective) of CZP associated with infliximab
14) Confidence 0.09 Published 2007 Journal Core Evidence Section Body Doc Link PMC3012434 Disease Relevance 0.21 Pain Relevance 0.29
Moreover, anti-infliximab antibodies did not cross-react with CZP in 20 patients with CD (Vetterlein et al. 2006), where anti-CZP antibody levels were undetectable, thus suggesting that CZP can be used in patients who develop an antibody response to infliximab.
Gene_expression (used) of CZP associated with infliximab and disease
15) Confidence 0.08 Published 2007 Journal Core Evidence Section Body Doc Link PMC3012434 Disease Relevance 0.24 Pain Relevance 0.30
The safety and economic profile of CZP, compared with available drugs (corticosteroids) also has to be considered in this scenario.
Gene_expression (profile) of CZP associated with corticosteroid
16) Confidence 0.08 Published 2007 Journal Core Evidence Section Body Doc Link PMC3012434 Disease Relevance 0.26 Pain Relevance 0.17
In conclusion, CZP is very promising and deserves attention but more studies, some of them in press or already ongoing, and the subsequent clinical application of the drug will provide the real definitive evidence for its use in CD.



Gene_expression (promising) of CZP associated with disease
17) Confidence 0.08 Published 2007 Journal Core Evidence Section Body Doc Link PMC3012434 Disease Relevance 0.23 Pain Relevance 0.08
Most adverse events were of mild to moderate severity; overall, the most common adverse events in patients receiving CZP were headache, nasopharyngitis (in both studies), abdominal pain (PRECiSE 1), and cough (PRECiSE 2).
Gene_expression (receiving) of CZP associated with abdominal pain, cough, nasopharyngitis and headache
18) Confidence 0.08 Published 2007 Journal Core Evidence Section Body Doc Link PMC3012434 Disease Relevance 1.79 Pain Relevance 0.34
Moreover, anti-infliximab antibodies did not cross-react with CZP in 20 patients with CD (Vetterlein et al. 2006), where anti-CZP antibody levels were undetectable, thus suggesting that CZP can be used in patients who develop an antibody response to infliximab.
Gene_expression (undetectable) of CZP associated with infliximab and disease
19) Confidence 0.08 Published 2007 Journal Core Evidence Section Body Doc Link PMC3012434 Disease Relevance 0.24 Pain Relevance 0.30

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox